Tag: Ppar alpha

According to a 2024 review, the endogenous fatty acid palmitoylethanolamide (PEA) demonstrates potential benefits for metabolic syndrome, including appetite regulation and enhanced energy expenditure, which directly counters the idea that palmitoylethanolamide causes weight gain. Instead, preclinical evidence points towards a role in supporting healthy body weight and fat mass.

According to a study published in the *Journal of Clinical Lipidology*, pharmacological doses of omega-3 fatty acids can reduce triglycerides by 20–30% or more, while fenofibrate has shown even more substantial reductions in some comparative trials. The question of whether fenofibrate is better than omega-3 for triglycerides is complex, depending on the severity of the condition, patient-specific factors, and overall lipid profile.